Daiichi Sankyo enters Japan's generics sector
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo, Japan's second-largest research-based pharmaceutical firm, has entered the growing domestic generics sector with the start of commercial operations at its new Daiichi Sankyo Espha subsidiary on 1 October.